이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Glenmark Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 4/6
Glenmark Pharmaceuticals 의 총 주주 지분은 ₹78.5B 이고 총 부채는 ₹9.9B, 이는 부채 대 자기자본 비율을 12.6% 로 가져옵니다. 총자산과 총부채는 각각 ₹143.6B 및 ₹65.1B 입니다. Glenmark Pharmaceuticals 의 EBIT는 ₹6.1B 이며 이자보상배율은 1.2 입니다. ₹16.6B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
12.6%
부채 비율
₹9.91b
부채
| 이자 보상 비율 | 1.2x |
| 현금 | ₹16.59b |
| 주식 | ₹78.48b |
| 총 부채 | ₹65.11b |
| 총 자산 | ₹143.59b |
최근 재무 상태 업데이트
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10재무 상태 분석
단기부채: GLENMARK 의 단기 자산 ( ₹74.3B )이 단기 부채( ₹58.2B ).
장기 부채: GLENMARK 의 단기 자산( ₹74.3B )이 장기 부채( ₹6.9B ).
부채 대 자본 내역 및 분석
부채 수준: GLENMARK 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: GLENMARK 의 부채 대 자기자본 비율은 지난 5년간 79.4% 에서 12.6% 로 감소했습니다.
부채 범위: GLENMARK 의 영업현금흐름이 마이너스이므로 부채가 제대로 상환되지 않습니다.
이자 보장: GLENMARK 의 부채에 대한 이자 지급은 EBIT( 1.2 x 적용 범위)만큼 잘 덮이지 않음입니다.